News &amp; Updates

Intermittent fasting (IF) appears to reduce cardiometabolic risk factors through the alteration of the gut microbial community and functional pathways in metabolic syndrome (MetS) patients, results of a recent study have shown.

Intermittent fasting improves cardiometabolic health in MetS patients

Late eating tied to cardiometabolic risk traits, impaired weight loss

21 Jan 2021 by

Eating late appears to induce the development of cardiometabolic risk factors and reduce the efficacy of weight-loss interventions, suggests a study.

Late eating tied to cardiometabolic risk traits, impaired weight loss

Adolescent NAFLD ups T2D risk in young adulthood

Nonalcoholic fatty liver disease (NAFLD) among normoglycaemic adolescents appears to increase the risk of type 2 diabetes (T2D), which may manifest before age 30 years, suggests a recent study.

Adolescent NAFLD ups T2D risk in young adulthood

Insulin clearance may be vascular damage indicator

Among people at risk of type 2 diabetes mellitus (T2DM), lowered insulin clearance may be an early indicator of vascular damage independently of other classical cardiovascular disease (CVD) risk factors, a recent study reports.

Insulin clearance may be vascular damage indicator

Computerized insulin dosing tool succeeds in diabetic ketoacidosis treatment

Use of the computerized insulin dosing tool (CIDT) with 24-hour pharmacist monitoring is efficacious and safe for the treatment of diabetic ketoacidosis (DKA) as compared with a provider-driven insulin dosing strategy, suggests a study.

Computerized insulin dosing tool succeeds in diabetic ketoacidosis treatment

Diabetic retinopathy tied to increased intubation risk in COVID-19

19 Jan 2021 by

Individuals with diabetic retinopathy who were hospitalized with COVID-19 had an elevated risk of requiring intubation, according to a recent study.

Diabetic retinopathy tied to increased intubation risk in COVID-19

Long-term tildrakizumab safe, effective in psoriatic patients with or without MetS

19 Jan 2021 by

The efficacy and safety of long-term tildrakizumab are comparable and maintained without evidence of reduced durability of response through 148 weeks of treatment in patients with and without metabolic syndrome (MetS), results from two phase III trials have shown.

Long-term tildrakizumab safe, effective in psoriatic patients with or without MetS

Alfacalcidol beneficial to patients undergoing valve-replacement surgery

Supplementation with alfacalcidol prior to valve-replacement surgery helps accelerate cardiac recovery, leading to shorter length of stay in the intensive care unit and the hospital, according to a study.

Alfacalcidol beneficial to patients undergoing valve-replacement surgery

Diabetes mellitus, lower myocardial perfusion worsen heart failure, death risk

Type 2 diabetes mellitus and a lowered myocardial perfusion seem to aggravate the risk of heart failure and/or all-cause mortality, a new study reports.

Diabetes mellitus, lower myocardial perfusion worsen heart failure, death risk

Higher dulaglutide doses improve response in T2D patients uncontrolled on metformin

Treatment with dulaglutide in type 2 diabetes (T2D) patients with inadequate response to metformin yields meaningful dose-related reductions in blood glucose and body weight without compromising safety, as shown in a study.

Higher dulaglutide doses improve response in T2D patients uncontrolled on metformin